Recent Announcements

28th October 2020

Irish Company Develop Technology Proven to Remove 99.99% of Coronavirus from Human Skin

Aquila Bioscience has successfully proven that its breakthrough Pathogen Capturing Technology safely removes 99.99% of SARS-CoV-2 from human skin. This is the first time a nature inspired, safe and non-toxic technology that is free from all harmful chemicals, has been proven to remove COVID-19 with such efficiency. The results show that this novel technology is equally if not more effective as the highest performing chemical-based methods currently on the market but without any of the environmental or health problems.

8th June 2020

Aquila Bioscience is selected for EIC Accelerator Funding

Aquila Bioscience has developed revolutionary decontamination technology that helps protect people from dangerous pathogens and other viral infections like coronavirus. We are delighted to receive funding from EIC which allows us to substantially scale up production and deliver this technology more quickly to frontline and other workers in Ireland and across the globe. This technology will make it safer for people to return to work and help get Ireland’s economy moving again.

29th May 2020

Aquila Bioscience Registered with FDA

Aquila Bioscience have been successfully registered as a foreign manufacturing facility with FDA under Owner/ Operator Number 10074735

The ABD Wipe product is registered with FDA under device listing D405606.

Aquila Bioscience are now permitted to market and sell the ABD Device in the US market.



ABD Technology at the 13th CBRNe Protection Symposium in Malmoe, Sweden

At the 13th CBRNe Protection Symposium in Malmoe (Sweden) ABD Technology was described to leading scientists, industries and end-users during a presentation ‘Biothreat Agent Protection: Novel approaches for capture, detection and decontamination’ (Session 4 – Hazard Management). For further information, please check out the meeting website here:


PATHSENSE ITN (H2020) secondment in Aquila Bioscience

Charlotte Dessaux, a French PhD student (ESR 4 in PathSense ITN), working at the Spanish National Centre for Biotechnology (CNB-CSIC) under supervision of Prof. Francisco Garcia del Portillo in Madrid (Spain), recently came to Galway for a month-long secondment in Aquila Bioscience to investigate bacterial glycan-lectin interactions in foodborne pathogens and to experience start-up SME environment. Charlotte presented her research at the 20th International Symposium on Problems of Listeria and Listeriosis (ISOPOL 2019) in Toronto, Canada. For further information, please check out the abstract submitted to ISOPOL 2019 under this link